FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes
- PMID: 37674691
- PMCID: PMC10477749
- DOI: 10.1016/j.xjidi.2023.100212
FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes
Abstract
The genomic basis of cutaneous T-cell lymphoma has been characterized by gene copy number alterations and genomic sequencing, but there are few clinical tests that are being widely used to inform the diagnosis and prognosis of leukemic cutaneous T-cell lymphoma that may arise as a progression from mycosis fungoides or de novo as Sézary syndrome. An 11-gene FISH panel of TP53, RB1, DNMT3A, FAS, ZEB1, ARID1A, ATM, and CDKN2A deletions and MYC, signal transducer and activator of transcription gene (STAT)3/5B, and CARD11 amplifications was previously found to encapsulate >95% of gene copy number variations in leukemic cutaneous T-cell lymphoma. Through a retrospective analysis of patients with leukemic cutaneous T-cell lymphoma seen at the Yale Cancer Center from 2014 to 2020, we gathered the relevant genes as they became available and correlated them to factors with prognostic relevance as a proof of concept to show the potential utility in further developing a limited gene panel for prognosis. In this study, we show that the abnormal FISH results show an association with clinically relevant factors (blood stage, CD4:8 ratio, and percentage blood involvement) and have a nonsignificant statistical trend (>90%) toward correlation with overall survival. In addition, the previous cost-effective panels were signal transducer and activator of transcription (STAT)3/5B, MYC, TP53, and ARID1A. We now suggest adding RB1 and ZEB1 on the basis of our findings.
© 2023 The Authors.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10477749/bin/gr1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10477749/bin/gr2.gif)
Similar articles
-
Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.Cell Death Dis. 2018 Dec 5;9(12):1178. doi: 10.1038/s41419-018-1212-7. Cell Death Dis. 2018. PMID: 30518749 Free PMC article.
-
Genetics Abnormalities with Clinical Impact in Primary Cutaneous Lymphomas.Cancers (Basel). 2022 Oct 11;14(20):4972. doi: 10.3390/cancers14204972. Cancers (Basel). 2022. PMID: 36291756 Free PMC article. Review.
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review.
-
Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.Leukemia. 1998 Apr;12(4):578-85. doi: 10.1038/sj.leu.2400956. Leukemia. 1998. PMID: 9557617 Review.
-
Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas.Clin Cancer Res. 2022 Jun 13;28(12):2610-2622. doi: 10.1158/1078-0432.CCR-21-4437. Clin Cancer Res. 2022. PMID: 35421230 Free PMC article.
References
-
- Bernengo M.G., Quaglino P., Novelli M., Cappello N., Doveil G.C., Lisa F., et al. Prognostic factors in Sezary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol. 1998;9:857–863. - PubMed
-
- Chang L.W., Patrone C.C., Yang W., Rabionet R., Gallardo F., Espinet B., et al. An integrated data resource for genomic analysis of cutaneous T-cell lymphoma. J Invest Dermatol. 2018;138:2681–2683. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous